Brain Trust Bio

Imagine you need to send a message to a friend. You could mail a letter and they might receive it in a few days. You could drive to their home to tell them the news, dealing with traffic along the way. But, wouldn’t it be simpler to just pick up your phone and call or text? It’s better. It’s faster. At Brain Trust Bio, we are giving life-altering medicines a direct route to the body without the roadblocks and side-effects commonly associated with other drug delivery methods. Now launching Phase I trials in Australia for our revolutionary Intrathecal Drug Delivery Method. The equivalence of these Phase I trials to American standards ensures that findings will be directly accepted in the U.S, allowing for an immediate advancement to Phase II without the need for repetition. Focusing on IT-Riluzole (the only drug demonstrated to prolong survival in ALS), the trials will involve 10 patients over a six-month period and will be conducted by leading medical professionals at Flinders University, Adelaide, and Sunshine Coast Hospital, Birtinya. Brain Trust Bio, an industry leader with a proven track record, which has already shown promising potential. Notably, two patients have been treated for over two years without observed side effects, offering promising indications of the method’s ability to extend life expectancy. We are committed to patients because with CNS disorders—like ALS and multiple sclerosis—every second, minute, or hour is more time with loved ones and a step closer to a cure. With ALS—the typical survival rate is two to five years from the time of diagnosis. During that time, those affected lose abilities we often take for granted like walking, talking, and eating independently. They miss important life events like birthdays, anniversaries, or their child’s graduation. Brain Trust Bio is making improvements to precision drug delivery and enhancing already available treatments to accelerate positive patient outcomes. Find out more at: